Oblato acquires all rights to glioblastoma drug from OMRF
October 29, 2018 11:21 ET
|
Oklahoma Medical Research Foundation
OKLAHOMA CITY, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Oblato, Inc., has acquired all rights from the Oklahoma Medical Research Foundation to OKN-007, an investigational drug for the treatment of...
Novel treatment of hemophilia: OMRF enters license agreement with Shanghai RAAS Blood Products
February 13, 2018 15:02 ET
|
Oklahoma Medical Research Foundation
OKLAHOMA CITY, Feb. 13, 2018 (GLOBE NEWSWIRE) -- The Oklahoma Medical Research Foundation has entered a license agreement with Shanghai RAAS Blood Products Co., Ltd. Under the agreement, Shanghai...
New tools for predicting lupus flares now one step closer to market
November 27, 2017 15:23 ET
|
Progentec Diagnostics, Inc.
OKLAHOMA CITY, Nov. 27, 2017 (GLOBE NEWSWIRE) -- Lead investor i2E, along with Chicago-based OCA Ventures and Mayo Clinic Ventures, has funded the first round of investment to assist Progentec in...